Literature DB >> 21984960

Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeutics.

Chuda Chittasupho1, Teruna J Siahaan, Charlotte M Vines, Cory Berkland.   

Abstract

Proteins participating in immunological signaling have emerged as important targets for controlling the immune response. A multitude of receptor-ligand pairs that regulate signaling pathways of the immune response have been identified. In the complex milieu of immune signaling, therapeutic agents targeting mediators of cellular signaling often either activate an inflammatory immune response or induce tolerance. This review is primarily focused on therapeutics that inhibit the inflammatory immune response by targeting membrane-bound proteins regulating costimulation or mediating immune-cell adhesion. Many of these signals participate in larger, organized structures such as the immunological synapse. Receptor clustering and arrangement into organized structures is also reviewed and emerging trends implicating a potential role for multivalent therapeutics is posited.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21984960      PMCID: PMC3186944          DOI: 10.4155/tde.11.60

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  159 in total

1.  A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease.

Authors:  Bruce Yacyshyn; William Y Chey; Mark K Wedel; Rosie Z Yu; David Paul; Emil Chuang
Journal:  Clin Gastroenterol Hepatol       Date:  2007-02       Impact factor: 11.382

2.  Switching from calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study.

Authors:  Lionel Rostaing; Pablo Massari; Valter Duro Garcia; Eduardo Mancilla-Urrea; Georgy Nainan; Maria del Carmen Rial; Steven Steinberg; Flavio Vincenti; Rebecca Shi; Greg Di Russo; Dolca Thomas; Josep Grinyó
Journal:  Clin J Am Soc Nephrol       Date:  2010-11-04       Impact factor: 8.237

3.  Endothelial targeting of high-affinity multivalent polymer nanocarriers directed to intercellular adhesion molecule 1.

Authors:  Silvia Muro; Thomas Dziubla; Weining Qiu; John Leferovich; Xiumin Cui; Erik Berk; Vladimir R Muzykantov
Journal:  J Pharmacol Exp Ther       Date:  2006-02-27       Impact factor: 4.030

4.  Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.

Authors:  Y Agata; A Kawasaki; H Nishimura; Y Ishida; T Tsubata; H Yagita; T Honjo
Journal:  Int Immunol       Date:  1996-05       Impact factor: 4.823

5.  Contribution of B7RP-1/ICOS co-stimulation to lethal acute GVHD.

Authors:  Junya Fujimura; Kazuyoshi Takeda; Yuki Kaduka; Masahoro Saito; Hisaya Akiba; Hideo Yagita; Yuichiro Yamashiro; Toshiaki Shimizu; Ko Okumura
Journal:  Pediatr Transplant       Date:  2010-02-01

6.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

Authors:  Jedd D Wolchok; Bart Neyns; Gerald Linette; Sylvie Negrier; Jose Lutzky; Luc Thomas; William Waterfield; Dirk Schadendorf; Michael Smylie; Troy Guthrie; Jean-Jacques Grob; Jason Chesney; Kevin Chin; Kun Chen; Axel Hoos; Steven J O'Day; Celeste Lebbé
Journal:  Lancet Oncol       Date:  2009-12-08       Impact factor: 41.316

7.  Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis.

Authors:  Alice B Gottlieb; Sewon Kang; Kenneth G Linden; Mark Lebwohl; Alan Menter; Ahsan A Abdulghani; Michael Goldfarb; Nicole Chieffo; Mark C Totoritis
Journal:  Clin Immunol       Date:  2004-04       Impact factor: 3.969

8.  Synthesis and evaluation of multivalent branched HPMA copolymer-Fab' conjugates targeted to the B-cell antigen CD20.

Authors:  Russell N Johnson; Pavla Kopecková; Jindrich Kopecek
Journal:  Bioconjug Chem       Date:  2009-01       Impact factor: 4.774

9.  Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

Authors:  Y Ishida; Y Agata; K Shibahara; T Honjo
Journal:  EMBO J       Date:  1992-11       Impact factor: 11.598

10.  ADAP-SLP-76 binding differentially regulates supramolecular activation cluster (SMAC) formation relative to T cell-APC conjugation.

Authors:  Hongyan Wang; Fiona E McCann; John D Gordan; Xiang Wu; Monika Raab; Talat H Malik; Daniel M Davis; Christopher E Rudd
Journal:  J Exp Med       Date:  2004-10-11       Impact factor: 14.307

View more
  9 in total

1.  A fibrinogen-derived peptide provides intercellular adhesion molecule-1-specific targeting and intraendothelial transport of polymer nanocarriers in human cell cultures and mice.

Authors:  Carmen Garnacho; Daniel Serrano; Silvia Muro
Journal:  J Pharmacol Exp Ther       Date:  2011-12-07       Impact factor: 4.030

Review 2.  Bioconjugate Strategies for the Induction of Antigen-Specific Tolerance in Autoimmune Diseases.

Authors:  Chunsong Yu; Jingchao Xi; Meng Li; Myunggi An; Haipeng Liu
Journal:  Bioconjug Chem       Date:  2017-12-06       Impact factor: 4.774

Review 3.  Peptides and peptidomimetics as immunomodulators.

Authors:  Ameya S Gokhale; Seetharama Satyanarayanajois
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

4.  Co-delivery of autoantigen and b7 pathway modulators suppresses experimental autoimmune encephalomyelitis.

Authors:  Laura Northrup; Joshua O Sestak; Bradley P Sullivan; Sharadvi Thati; Brittany L Hartwell; Teruna J Siahaan; Charlotte M Vines; Cory Berkland
Journal:  AAPS J       Date:  2014-10-09       Impact factor: 4.009

5.  A quantitative view of strategies to engineer cell-selective ligand binding.

Authors:  Zhixin Cyrillus Tan; Brian T Orcutt-Jahns; Aaron S Meyer
Journal:  Integr Biol (Camb)       Date:  2021-12-30       Impact factor: 2.192

6.  Immune Tolerance Induction against Experimental Autoimmune Encephalomyelitis (EAE) Using A New PLP-B7AP Conjugate that Simultaneously Targets B7/CD28 Costimulatory Signal and TCR/MHC-II Signal.

Authors:  Ahmed H Badawi; Paul Kiptoo; Teruna J Siahaan
Journal:  J Mult Scler (Foster City)       Date:  2015-12

7.  A Multivalent ICAM-1 Binding Nanoparticle which Inhibits ICAM-1 and LFA-1 Interaction Represents a New Tool for the Investigation of Autoimmune-Mediated Dry Eye.

Authors:  Pang-Yu Hsueh; Yaping Ju; Adrianna Vega; Maria C Edman; J Andrew MacKay; Sarah F Hamm-Alvarez
Journal:  Int J Mol Sci       Date:  2020-04-15       Impact factor: 5.923

Review 8.  B cell depletion therapies in autoimmune disease: advances and mechanistic insights.

Authors:  Dennis S W Lee; Olga L Rojas; Jennifer L Gommerman
Journal:  Nat Rev Drug Discov       Date:  2020-12-15       Impact factor: 84.694

Review 9.  B-cell targeted therapeutics in clinical development.

Authors:  Stephan Blüml; Kathleen McKeever; Rachel Ettinger; Josef Smolen; Ronald Herbst
Journal:  Arthritis Res Ther       Date:  2013-04-04       Impact factor: 5.156

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.